Sugi Predict

Sugi Predict / Compounds / SCHEMBL527746

SCHEMBL527746

SCHEMBL527746

COC(=O)c1cccc2c(Cl)ncnc12

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PSMD14 O00487 1/20 0.46
▸ KDM4E B2RXH2 4/20 0.44
▸ NR4A2 P43354 1/20 0.44
▸ LPAR1 Q92633 1/20 0.43
▸ LPAR2 Q9HBW0 1/20 0.43
▸ MAP2K1 Q02750 1/20 0.42
▸ AURKA O14965 6/20 0.42
▸ RPS6KB1 P23443 6/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ GAA P10253 1/20 0.42
▸ ATM Q13315 1/20 0.42
▸ PIM1 P11309 1/20 0.41
▸ PIM2 Q9P1W9 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ SLC6A4 P31645 1/20 0.41
▸ SLC6A3 Q01959 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.40
▸ MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12786651 0.84 TSHR (0.50) KDM4EKMT2ATSHRALDH1A1MAPT
SCHEMBL667108 0.83 KDM4E (0.49) PSMD14KDM4EMAP2K1AURKARPS6KB1
SCHEMBL1461852 0.81 PDE4A (0.43) AURKARPS6KB1LMNA
SCHEMBL8511274 0.81 SMN1; SMN2 (0.49) PSMD14KDM4ENR4A2AURKARPS6KB1
SCHEMBL23497108 0.80 RPS6KB1 (0.39) KDM4EAURKARPS6KB1GAA
SCHEMBL3642037 0.80 RPS6KB1 (0.43) KDM4EAURKARPS6KB1KMT2AGAA
SCHEMBL23293688 0.79 PSMD14 (0.56) PSMD14KDM4ENR4A2MAP2K1KMT2A
SCHEMBL666532 0.79 TP53 (0.46) PSMD14KDM4ENR4A2KMT2ASLC6A4
SCHEMBL528027 0.78 KDM4E (0.50) PSMD14KDM4ENR4A2KMT2AGAA
SCHEMBL1462290 0.78 CSNK2A1 (0.39) PSMD14KDM4ENR4A2AURKARPS6KB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12404270-B2 Quinazoline derivatives as LPA receptor 2 inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2025-09-02 — — US disclosed
WO-2025129167-A1 INHIBITORS OF THE SURFACE EXPRESSION OF THE VOLTAGE-GATED SODIUM ION CHANNEL 1.7 (NAV1.7) AND THEIR THERAPEUTIC USES THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) 2025-06-19 — — WO disclosed
EP-4072670-B1 QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS CHIESI FARM SPA (IT) 2023-11-22 — — EP disclosed
US-20230063121-A1 QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2023-03-02 — — US disclosed
EP-4072670-A1 QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2022-10-19 — — EP disclosed
CN-114786771-A Quinazoline derivatives as inhibitors of LPA receptor 2 奇斯药制品公司 2022-07-22 — — CN disclosed
WO-2021116260-A1 QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2021-06-17 — — WO disclosed
US-10087166-B2 Cyclic amine azaheterocyclic carboxamides MERCK PATENT GMBH (DE) 2018-10-02 — — US disclosed
US-20170129877-A1 Cyclic Amine Azaheterocyclic Carboxamides MERCK PATENT GMBH (DE) 2017-05-11 — — US disclosed
US-20170129877-A1 Cyclic Amine Azaheterocyclic Carboxamides MERCK PATENT GMBH (DE) 2017-05-11 — — US disclosed
US-20130217709-A1 Cyclic Amine Azaheterocyclic Carboxamides MERCK PATENT GMBH (DE) 2013-08-22 — — US disclosed
EP-2598497-A1 CYCLIC AMINE AZAHETEROCYCLIC CARBOXAMIDES Merck Patent GmbH (DE) 2013-06-05 — — EP disclosed
US-20120046269-A1 Novel Amino Azaheterocyclic Carboxamides MERCK PATENT GMBH (DE) 2012-02-23 — — US disclosed
US-20120046269-A1 Novel Amino Azaheterocyclic Carboxamides MERCK PATENT GMBH (DE) 2012-02-23 — — US disclosed
US-20120046269-A1 Novel Amino Azaheterocyclic Carboxamides MERCK PATENT GMBH (DE) 2012-02-23 — — US disclosed
WO-2012016001-A1 CYCLIC AMINE AZAHETEROCYCLIC CARBOXAMIDES MERCK PATENT GMBH (DE) 2012-02-02 — — WO disclosed
WO-2012016001-A1 CYCLIC AMINE AZAHETEROCYCLIC CARBOXAMIDES MERCK PATENT GMBH (DE) 2012-02-02 — — WO disclosed
EP-2396307-A1 NOVEL AMINO AZAHETEROCYCLIC CARBOXAMIDES Merck Patent GmbH (DE) 2011-12-21 — — EP disclosed
WO-2010093419-A1 NOVEL AMINO AZAHETEROCYCLIC CARBOXAMIDES MERCK PATENT GMBH (DE) 2010-08-19 — — WO disclosed
WO-2010093419-A1 NOVEL AMINO AZAHETEROCYCLIC CARBOXAMIDES MERCK PATENT GMBH (DE) 2010-08-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12404270-B2 Quinazoline derivatives as LPA receptor 2 inhibitors LPAR2, LPAR1, LPAR5 PSMD14 4463/4885KDM4E 3035/4885NR4A2 917/4885
US-20130217709-A1 Cyclic Amine Azaheterocyclic Carboxamides MKI67, AZI2, PCNA PSMD14 3211/4885KDM4E 507/4885NR4A2 621/4885
US-20120046269-A1 Novel Amino Azaheterocyclic Carboxamides AZI2, MKI67, MYC PSMD14 2683/4885KDM4E 272/4885NR4A2 388/4885
US-20170129877-A1 Cyclic Amine Azaheterocyclic Carboxamides MKI67, AZI2, PCNA PSMD14 3211/4885KDM4E 507/4885NR4A2 621/4885
US-20230063121-A1 QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS LPAR2, LPAR1, LPAR5 PSMD14 4463/4885KDM4E 3035/4885NR4A2 917/4885
US-10087166-B2 Cyclic amine azaheterocyclic carboxamides MKI67, AZI2, PCNA PSMD14 3211/4885KDM4E 507/4885NR4A2 621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.